MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
Rhea-AI Summary
MoonLake Immunotherapeutics (NASDAQ: MLTX) priced an upsized underwritten public offering raising about $200 million in gross proceeds. The deal includes 9,000,000 Class A shares at $20.00 plus pre-funded warrants for up to 1,000,000 shares at $19.9999.
Underwriters hold a 30-day option to buy up to 1,500,000 additional shares. Closing is expected around June 25, 2026, subject to customary conditions. MoonLake plans to use net proceeds, with existing cash, to fund sonelokimab research, development, and potential commercialization, and for general corporate purposes.
Positive
- Approximately $200 million in gross proceeds to strengthen MoonLake’s cash position
- Offering of 9,000,000 new shares at a defined price of $20.00
- Additional 1,000,000 shares via immediately exercisable pre-funded warrants
- Underwriters’ 30-day option for up to 1,500,000 extra shares provides incremental capital potential
- Proceeds earmarked to fund sonelokimab R&D, pre-commercial and commercialization activities
Negative
- Equity issuance of up to 10,000,000 shares plus 1,500,000 overallotment implies shareholder dilution
- Underwriting discounts, commissions and expenses will reduce the $200 million gross proceeds to lower net proceeds
News Market Reaction – MLTX
In the Jun 24 session, MLTX declined 5.75%, reflecting a notable negative market reaction. Argus tracked a trough of -9.5% from its starting point during tracking. Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility. Trading volume was elevated at 2.0x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 05 | Equity offering | Neutral | +4.5% | Underwritten $75M equity raise to fund sonelokimab R&D and operations. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The only prior offering headline in the last year coincided with a moderate positive move of 4.54%.
Key Terms
underwritten public offering financial
pre-funded warrants financial
shelf registration statement regulatory
prospectus supplement regulatory
free writing prospectus regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
ZUG, Switzerland, June 23, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced the pricing of an underwritten public offering of 9,000,000 Class A ordinary shares at a public offering price per share of
MoonLake intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities, to fund the research, development, pre-commercialization activities and commercialization activities of sonelokimab, if approved, and for general corporate purposes.
Leerink Partners, Guggenheim Securities, Cantor and LifeSci Capital are acting as joint bookrunning managers for the offering. H.C. Wainwright & Co. and Clear Street are acting as lead managers for the offering.
A shelf registration statement relating to these securities has been filed with the Securities and Exchange Commission (“SEC”) and became effective on September 11, 2023. The offering is being made only by means of a prospectus, including a prospectus supplement, as may be further supplemented by any free writing prospectus and/or pricing supplement that MoonLake may file with the SEC, forming a part of an effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website, located at www.sec.gov. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Electronic copies of the prospectus supplement and accompanying prospectus may also be obtained, when available, by contacting Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, New York 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by email at prospectus@cantor.com; or LifeSci Capital LLC at 1700 Broadway, 40th Floor, New York, New York 10019, or by email at legalnotices@lifescicapital.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody® for the treatment of inflammatory disease, to revolutionize outcomes for patients. Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. MoonLake’s focus is on inflammatory diseases with a major unmet need, including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis and palmoplantar pustulosis – conditions affecting millions of people worldwide with a large need for improved treatment options. MoonLake was founded in 2021 and is headquartered in Zug, Switzerland.
Forward-Looking Statements
This press release contains certain “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements include, but are not limited to, statements regarding MoonLake’s expectations regarding the consummation of the offering, the anticipated use of the net proceeds of the offering and the satisfaction of customary closing conditions with respect to the offering. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that the statement is not forward looking.
Forward-looking statements are based on current expectations and assumptions that, while considered reasonable by MoonLake and its management, as the case may be, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, our capital position and the sufficiency of our capital to fund our operations in future periods; changes as a result of market conditions or for other reasons; the risk that the offering will not be consummated; the impact of general economic, health, industrial or political conditions in the United States or internationally; and other risks and uncertainties identified in MoonLake’s Annual Report on Form 10-K for the year ended December 31, 2025, Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and other subsequent disclosure documents filed with the SEC.
Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. MoonLake does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or in the events, conditions or circumstances on which any such statement is based.
Contacts:
MoonLake Immunotherapeutics Media & Investors Relations
ir@moonlaketx.com
ICR Healthcare
Mary-Jane Elliott, Namrata Taak, Ashley Tapp
Tel: +44 (0) 20 3709 5700
MoonLake@ICRHealthcare.com
